Skip to main content
Top
Published in: Journal of Gastroenterology 4/2013

01-04-2013 | Letter to the Editor

Reply to the letter by Lai et al. regarding “Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal study”

Authors: Teruki Miyake, Teru Kumagi, Shinya Furukawa, Masanori Abe, Yoichi Hiasa, Bunzo Matsuura, Morikazu Onji

Published in: Journal of Gastroenterology | Issue 4/2013

Login to get access

Excerpt

We thank Lai et al. for their letter showing interest in our paper [1]. We agree with their opinion that body mass index (BMI) is useful to identify individuals at risk of developing nonalcoholic fatty liver disease (NAFLD), as well as to predict the presence of NAFLD in primary care settings. Previously, they examined the relationship between NAFLD and cardiovascular risk factors in a hospital-based, cross-sectional study [2]. In this study, they defined generalized obesity as a BMI of at least 27 kg/m2 as recommended by the Bureau of Health Promotion, Department of Health, Taiwan [3], and identified male gender, generalized obesity, central obesity, hyperglycemia, hypercholesterolemia, a high level of LDL-C, a low level of HDL-C, and hyperuricemia as the related factors for the presence of NAFLD [2]. Eguchi et al. also reported in a multicenter, large, retrospective study among the general population that BMI was also a useful marker for identifying NAFLD subjects. They showed that BMI in subjects with NAFLD was significantly higher than in those without NAFLD (p < 0.01), and the prevalence of NAFLD showed a linear increase with the increase of BMI (BMI < 23 kg/m2, 10.5 %; 23 ≤ BMI < 25 kg/m2, 37.9 %; 25 ≤ BMI < 28 kg/m2, 58.4 %; BMI ≥ 28 kg/m2, 84.2 %) [4]. …
Literature
1.
go back to reference Miyake T, Kumagi T, Hirooka M, et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol. 2012 doi:10.1007/s00535-012-0650-8. Miyake T, Kumagi T, Hirooka M, et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol. 2012 doi:10.​1007/​s00535-012-0650-8.
2.
go back to reference Lai HC, Lin T, Lai SW, Liao KF. Association between nonalcoholic fatty liver disease and cardiovascular risk factors in a hospital-based study. Tzu Chi Med J. 2008;20:213–7.CrossRef Lai HC, Lin T, Lai SW, Liao KF. Association between nonalcoholic fatty liver disease and cardiovascular risk factors in a hospital-based study. Tzu Chi Med J. 2008;20:213–7.CrossRef
4.
go back to reference Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.PubMedCrossRef Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586–95.PubMedCrossRef
5.
go back to reference Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009;44:1203–8.PubMedCrossRef Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009;44:1203–8.PubMedCrossRef
6.
go back to reference Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–9.PubMedCrossRef Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–9.PubMedCrossRef
7.
go back to reference Miyake T, Kumagi T, Hirooka M, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696–703.PubMedCrossRef Miyake T, Kumagi T, Hirooka M, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696–703.PubMedCrossRef
Metadata
Title
Reply to the letter by Lai et al. regarding “Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal study”
Authors
Teruki Miyake
Teru Kumagi
Shinya Furukawa
Masanori Abe
Yoichi Hiasa
Bunzo Matsuura
Morikazu Onji
Publication date
01-04-2013
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 4/2013
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0735-4

Other articles of this Issue 4/2013

Journal of Gastroenterology 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine